Cardiovascular Disease

Patients with Ehlers-Danlos syndrome experience significantly more prevalent gastrointestinal, cardiovascular, autonomic and allergic symptoms than those in the hospital without the disease, according to data published in Rheumatology.

For patients with hypertension, variation in eGFR measurements over time appeared to increase risk for all-cause mortality but did not demonstrate an association with cardiovascular events.

Increased physical activity may mitigate risk for CVD regardless of BMI, but elevated BMI itself remains a significant CVD risk factor, according to data published in the European Journal of Preventive Cardiology.

Cardiovascular disease incidence among women and patients younger than 55 years with rheumatoid arthritis is higher than their typical “low risk” classification would suggest, according to data published in Arthritis Research & Therapy.

The American Heart Association and the American Medical Society for Sports Medicine created a national registry to track COVID-19 cases and CVD in NCAA athletes, according to a press release.

As part of the 2020 Year in Review, Cardiology Today compiled a list of selected drugs and devices related to the specialty that were newly approved or cleared or were granted a new indication. Information was gathered from the FDA website and news releases. We put our best effort into making a complete list and regret any omissions. Appearance of a drug or device does not constitute any endorsement by Cardiology Today, its editors, publisher or editorial board. – The Editors

The January issue of Cardiology Today traditionally features a list of the Top 10 Stories of the Year in CVD, selected by the Cardiology Today Editorial Board. Clearly, the top news of 2020 was the novel coronavirus. In this issue, the Editors and I acknowledge that and break from tradition.

There has been much discussion about patient-centered outcomes in CVD therapy and treatment, but little consensus exists as to their definition and value.

High HDL cholesterol levels alone may not be cardioprotective for midlife women; estradiol may influence the risk for cardiovascular disease, according to data from the SWAN Heart study.

Adults who were born prematurely may be at an elevated risk for premature death from all causes, as well as death from noncommunicable diseases such as CVD, chronic lung disease and diabetes, according to research published in JAMA Network Open.